Small-molecule inhibitors of DNA damage-repair pathways: An approach to overcome tumor resistance to alkylating anticancer drugs

Future Medicinal Chemistry

Volumn 4, Issue 9, 2012, Pages 1093-1111

  Srinivasan, Ajay ^a   Gold, Barry ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APE 1 INHIBITOR; DNA; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; DNA DIRECTED DNA POLYMERASE BETA; DNA DIRECTED DNA POLYMERASE BETA INHIBITOR; DNA GLYCOSYLTRANSFERASE; ENZYME INHIBITOR; FEN 1 INHIBITOR; FEN 1 PROTEIN; FLAP ENDONUCLEASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1 INHIBITOR; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; POLYDEOXYRIBONUCLEOTIDE SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ALKYLATION; APOPTOSIS; CANCER RESISTANCE; CELL CYCLE ARREST; CRYSTAL STRUCTURE; CYTOTOXICITY; DNA DAMAGE; DNA REPAIR; ENZYME ACTIVITY; EPIGENETICS; EXCISION REPAIR; HUMAN; IC 50; PRIORITY JOURNAL; REVIEW;

ANTINEOPLASTIC AGENTS, ALKYLATING; DNA DAMAGE; DNA REPAIR; DRUG RESISTANCE, NEOPLASM; HUMANS;

EID: 84862587842     PISSN: 17568919     EISSN: 17568927     Source Type: Journal    
DOI: 10.4155/fmc.12.58     Document Type: Review

References (150)

1. Weinberg RA. The Biology of Cancer. Garland Science, New York, NY, USA (2006).
2. Valabrega G, Montemurro F, Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann. Oncol. 18, 977-984 (2007). (Pubitemid 47050487)
3. Fiszman GL, Jasnis MA. Molecular mechanisms of trastuzumab resistance in HER2 overexpressing breast cancer. Int. J. Breast Cancer 2011, 352182 (2011).
4. Molina MA, Sáez R, Ramsey EE et al. NH2-terminal truncated HER-2 protein but not full-length receptor is associated with nodal metastasis in human breast cancer. Clin. Cancer Res. 8, 347-353 (2002). (Pubitemid 34193949)
5. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res. 62, 4132-4141 (2002). (Pubitemid 34791085)
6. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-non growth factor-I receptor signaling and resistance to transtuzumab (herceptin). J. Natl Cancer Inst. 93, 1852-1857 (2001). (Pubitemid 34048651)
7. Barok M, Isola J, Pályi-Krekk Z et al. Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance. Mol. Cancer Ther. 6, 2065-2072 (2007). (Pubitemid 47052497)
8. Boeckmann L, Nickel AC, Kuschal C et al. Temozolomide chemoresistance heterogeneity in melanoma with different treatment regimens: DNA damage accumulation contribution. Melanoma Res. 21, 206-216 (2011).
9. Beier D, Schulz JB, Beier CP. Chemoresistance of glioblastoma cancer stem cells-much more complex than expected. Mol. Cancer 10, 128-138 (2011).
10. Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat. Rev. 31, 603-617 (2005). (Pubitemid 41662887)
11. Adhikari S, Choudhury S, Mitra PS, Dubash JJ, Sajankila SP, Roy R. Targeting base excision repair for chemosensitization. Anticancer Agents Med. Chem. 8, 351-357 (2008). (Pubitemid 351761420)
12. Jalal S, Earley JN, Turchi JJ. DNA repair: from genome maintenance to biomarker and therapeutic target. Clin. Cancer Res. 17, 6973-6984 (2011).
13. Ghabili K, Agutter PS, Ghanei M, Ansarin K, Panahi Y, Shoja MM. Sulfur mustard toxicity: history, chemistry, pharmacokinetics, and pharmacodynamics. Crit. Rev. Toxicol. 41, 384-403 (2011).
14. Kohn KW. Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1- nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas. Cancer Res. 37, 1450-1454 (1977). (Pubitemid 8104887)
15. Foye LV Jr, Chapman CG, Willett FM, Adams WS. A preliminary study of a new alkylating agent. Cyclophosphamide. Cancer Chemother. Rep. 6, 39-40 (1977).
16. Tokuda K, Bodell WJ. Cytotoxicity and sister chromatid exchanges in 9L cells treated with monofunctional and bifunctional nitrogen mustards. Carcinogenesis 8, 1697-1701 (1987). (Pubitemid 18038641)
17. Shrivastav N, Li D, Essigmann JM. Chemical biology of mutagenesis and DNA repair: cellular responses to DNA alkylation. Carcinogenesis 31, 59-70 (2010).
18. Marchesi F, Turriziani M, Tortorelli G, Avvisati G, Torino F, De Vecchis L. Triazene compounds: mechanism of action and related DNA repair systems. Pharmacol. Res. 56, 275-287 (2007). (Pubitemid 47488901)
19. Hijiya N, Hudson MM, Lensing S et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. J. Am. Med. Assoc. 297, 1207-1215 (2007). (Pubitemid 46465729)
20. Hijiya N, Ness KK, Ribeiro RC, Hudson MM. Acute leukemia as a secondary malignancy in children and adolescents: current findings and issues. Cancer 115, 23-35 (2009).
21. Inga A, Chen F-X, Monti P et al. N-(2-chloroethy)-N-nitrosourea tethered to lexitropsin induces minor groove lesions at the p53 cDNA which are more cytotoxic than mutagenic. Cancer Res. 59, 689-695 (1999). (Pubitemid 29076069)
22. Monti PA, Campomenosi P, Iannone R et al. Influences of base excision repair defects on the lethality and mutagenesis induced by Me-lex, a sequence selective N3-adenine methylating agent. J. Biol. Chem. 277, 28663-28668 (2002).
23. Gold B, Fronza G. The biological effects of N3-methyladenine. J. Cell. Biochem. 91, 250-257 (2004).
24. Bobola MS, Varadarajan S, Smith NW et al. Human glioma cell sensitivity to the sequence-specific alkylating agent methyl-lexitropsin. Clin. Cancer Res. 13, 612-620 (2007). (Pubitemid 46225368)
25. Türk D, Szakács G. Relevance of multidrug resistance in the age of targeted therapy. Curr. Opin. Drug Discov. Devel. 12, 246-252 (2009).
26. Baumert C, Hilgeroth A. Recent advances in the development of P-gp inhibitors. Anticancer Agents Med. Chem. 9, 415-436 (2009).
27. Gangemi R, Paleari L, Orengo AM et al. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr. Med. Chem. 16, 1688-1703 (2009).
28. Baguley BC. Multiple drug resistance mechanisms in cancer. Mol. Biotechnol. 46, 308-316 (2010).
29. Liu J, Powell KL, Thames HD, MacLeod MC. Detoxication of sulfur half-mustards by nucleophilic scavengers: robust activity of thiopurines. Chem. Res. Toxicol. 23, 488-496 (2010).
30. Abel EL, Bubel JD, Simper MS et al. Protection against 2-chloroethyl ethyl sulfide (CEES)-induced cytotoxicity in human keratinocytes by an inducer of the glutathione detoxification pathway. Toxicol. Appl. Pharmacol. 255, 176-183 (2010).
31. Sobol RW, Watson DE, Nakamura J et al. Mutations associated with base excision repair deficiency and methylation-induced genotoxic stress. Proc. Natl Acad. Sci. USA 99, 6860-6865 (2002). (Pubitemid 34526223)
32. Bobola MS, Finn LS, Ellenbogen RG et al. Apurinic/apyrimidinic endonuclease activity is associated with response to radiation and chemotherapy in medulloblastoma and primitive neuroectodermal tumors. Clin. Cancer Res. 11, 7405-7414 (2005). (Pubitemid 41507701)
33. Ono Y, Furuta T, Ohmoto T, Akiyama K, Seki S. Stable expression in rat glioma cells of sense and antisense nucleic acids to a human multifunctional DNA repair enzyme, APEX nuclease. Mutat. Res. 315, 55-63 (1994). (Pubitemid 24208288)
34. Walker LJ, Craig RB, Harris AL, Hickson ID. A role for the human DNA repair enzyme HAP1 in cellular protection against DNA damaging agents and hypoxic stress. Nucleic Acids Res. 22, 4884-4889 (1994).
35. Silber JR, Bobola MS, Blank A et al. The apurinic/apyrimidinic endonuclease activity of Ape1/Ref-1 contributes to human glioma cell resistance to alkylating agents and is elevated by oxidative stress. Clin. Cancer Res. 8, 3008-3018 (2003). (Pubitemid 35025751)
36. Liu L, Gerson SL. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr. Opin. Investig. Drugs 5, 623-627 (2004).
37. Engelward BP, Weeda G, Wyatt MD et al. Base excision repair deficient mice lacking the Aag DNA glycosylase. Proc. Natl Acad. Sci. USA 94, 13087-13092 (1997). (Pubitemid 27518480)
38. Wirtz S, Nagel G, Eshkind L, Neurath MF, Samson LD, Kaina B. Both base excision repair and O6-methylguanine-DNA methyltransferase protect against methylation-induced colon carcinogenesis. Carcinogenesis 31, 2111-2117 (2010).
39. Kisby GE, Olivas A, Park T et al. DNA repair modulates the vulnerability of the developing brain to alkylating agents. DNA Repair 8, 400-412 (2009).
40. Liu L, Yan L, Donze JR, Gerson SL. Blockage of abasic site repair enhances antitumor efficacy of 1,3-bis-(2-chloroethyl)-1-nitrosourea in colon tumor xenografts. Mol. Cancer Ther. 2, 1061-1066 (2003).
41. Kruse V, Rottey S, De Backer O, Van Belle S, Cocquyt V, Denys H. PARP inhibitors in oncology: a new synthetic lethal approach to cancer therapy. Acta Clin. Belg. 66, 2-9 (2011).
42. Rinne M, Caldwell D, Kelley MR. Transient adenoviral N-methylpurine DNA glycosylase overexpression imparts chemotherapeutic sensitivity to human breast cancer cells. Mol. Cancer Ther. 3, 955-967 (2004). (Pubitemid 39199590)
43. Trivedi RN, Wang XH, Jelezcova E, Goellner EM, Tang JB, Sobol RW. Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide. Mol. Pharmacol. 74, 505-516 (2008).
44. Sarasin A, Kauffmann A. Overexpression of DNA repair genes is associated with metastasis: a new hypothesis. Mutat. Res. 659, 49-55 (2008).
45. Kauffmann A, Rosselli F, Lazar V et al. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene 27, 565-573 (2008). (Pubitemid 351158908)
46. Fan J, Robert C, Jang YY et al. Human induced pluripotent cells resemble embryonic stem cells demonstrating enhanced levels of DNA repair and efficacy of nonhomologous end-joining. Mutat. Res. 713, 8-17 (2011).
47. Niedernhofer LJ. DNA repair is crucial for maintaining hematopoietic stem cell function. DNA Repair 7, 523-529 (2008).
48. Tichy ED, Stambrook PJ. DNA repair in murine embryonic stem cells and differentiated cells. Exp. Cell Res. 314, 1929-1936 (2008).
49. Tichy ED, Liang L, Deng L et al. Mismatch and base excision repair proficiency in murine embryonic stem cells. DNA Repair 10, 445-451 (2011).
50. Hegde ML, Hazra TK, Mitra S. Early steps in the DNA base excision/single-strand interruption repair pathway in mammalian cells. Cell Res. 18, 27-47 (2008).
51. Jackson AL, Loeb LA. The contribution of endogenous sources of DNA damage to the multiple mutations in cancer. Mutat. Res. 477, 7-21 (2001). (Pubitemid 32480184)
52. Martinez GR, Loureiro AP, Marques SA et al. Oxidative and alkylating damage in DNA. Mutat. Res. 544, 115-127 (2003). (Pubitemid 37487655)
53. Kow YW. Repair of deaminated bases in DNA. Free Radic. Biol. Med. 33, 886-893 (2002). (Pubitemid 35284028)
54. Marnett LJ. Oxy radicals, lipid peroxidation and DNA damage. Toxicology 181-182, 219-222 (2002). (Pubitemid 36015702)
55. Fronza G, Gold B. The biological effects of N3-methyladenine. J. Cell. Biochem. 91, 250-257 (2004).
56. Larson K, Sahm J, Shenkar R, Strauss, B. Methylation-induced blocks to in vitro DNA replication. Mutat. Res. 150, 77-84 (1985). (Pubitemid 15226334)
57. Paik J, Duncan T, Lindahl T, Sedgwick B. Sensitization of human carcinoma cells to alkylating agents by small interfering RNA suppression of 3-alkyladenine-DNA glycosylase. Cancer Res. 65, 10472-10477 (2005). (Pubitemid 41743742)
58. Bobola MS, Varadarajan S, Smith NW et al. Human glioma cell sensitivity to the sequence-specific alkylating agent methyl-lexitropsin. Clin. Cancer Res. 13, 612-620 (2007). (Pubitemid 46225368)
59. Lau AY, Wyatt MD, Glassner BJ, Samson LD, Ellenberger T. Molecular basis for discriminating between normal and damaged bases by the human alkyladenine glycosylase, AAG. Proc. Natl Acad. Sci. USA 97, 13573-13578 (2000).
60. Speina E, Cie?la JM, Graziewicz MA, Laval J, Kazimierczuk Z, Tudek B. Inhibition of DNA repair glycosylases by base analogs and tryptophan pyrolysate, Trp-P-1. Acta Biochim. Pol. 52, 167-178 (2005). (Pubitemid 41132185)
61. Hegde ML, Hazra TK, Mitra S. Functions of disordered regions in mammalian early base excision repair proteins. Cell. Mol. Life Sci. 67, 3573-3587 (2010).
62. Setser JW, Lingaraju GM, Davis CA, Samson LD, Drennan CL. Searching for DNA lesions: structural evidence for lower-and higher-affinity DNA binding conformations of human alkyladenine DNA glycosylase. Biochemistry 51, 382-390 (2012).
63. Klapacz J, Lingaraju GM, Guo HH et al. Frameshift mutagenesis and microsatellite instability induced by human alkyladenine DNA glycosylase. Mol. Cell 37, 843-853 (2010).
64. Fujii T, Saito T, Nakasaka T. Purines. XXXIV. 3-methyladenosine and 3-methyl-2'-deoxyadenosine: their synthesis, glycosidic hydrolysis, and ring fission. Chem. Pharm. Bull. 37, 2601-2609 (1989). (Pubitemid 19279372)
65. Lindahl T. Instability and decay of the primary structure of DNA. Nature 362, 709-715 (1993). (Pubitemid 23125973)
66. Nakamura J, Swenberg JA. Endogenous apurinic/apyrimidinic sites in genomic DNA of mammalian tissues. Cancer Res. 59, 2522-2526 (1999). (Pubitemid 29269091)
67. Xanthoudakis S, Curran T. Redox regulation of AP-1: a link between transcription factor signaling and DNA repair. Adv. Exp. Med. Biol. 387, 69-75 (1996). (Pubitemid 26259231)
68. Chang IY, Kim JN, Jun JY et al. Repression of apurinic/apyrimidinic endonuclease by p53-dependent apoptosis in hydronephrosis-induced rat kidney. Free Radic. Res. 45, 728-734 (2011).
69. Fung H, Demple B. Distinct roles of Ape1 protein in the repair of DNA damage induced by ionizing radiation or bleomycin. J. Biol. Chem. 286, 4968-4977 (2011).
70. Fung H, Demple B. Overexpression of APE-1 makes cells resistant to alkylating agents. A vital role for Ape1/Ref1 protein in repairing spontaneous DNA damage in human cells. Mol. Cell 17, 463-470 (2005). (Pubitemid 40193316)
71. McNeill DR, Wilson DM. III A dominant-negative form of the major human abasic endonuclease enhances cellular sensitivity to laboratory and clinical DNA-damaging agents. Mol. Cancer Res. 5, 61-70 (2007).
72. Jiang Y, Guo C, Vasko MR, Kelley MR. Implications of apurinic/ apyrimidinic endonuclease in reactive oxygen signaling response after cisplatin treatment of dorsal root ganglion neurons. Cancer Res. 68, 6425-6434 (2008).
73. Evans AR, Limp-Foster M, Kelley MR. Going APE over ref-1. Mutat. Res. 461, 83-108 (2000).
74. Fritz G. Human APE/Ref-1 protein. Int. J. Biochem. Cell Biol. 32, 925-929 (2000).
75. Tell G, Quadrifoglio F, Tiribelli C, Kelley MR. The many functions of APE1/Ref-1: not only a DNA repair enzyme. Antioxid. Redox Signal. 11, 601-620 (2009).
76. Su D, Delaplane S, Luo M et al. Interactions of apurinic/apyrimidinic endonuclease with a redox inhibitor: evidence for an alternate conformation of the enzyme. Biochemistry 50, 82-92 (2010).
77. Mol CD, Izumi T, Mitra S, Tainer JA. DNA-bound structures and mutants reveal abasic DNA binding by APE1 and DNA repair coordination. Nature 403, 451-456 (2000). (Pubitemid 30073097)
78. Mohammed MZ, Vyjayanti VN, Laughton CA et al. Development and evaluation of human AP endonuclease inhibitors in melanoma and glioma cell lines. Br. J. Cancer 104, 653-663 (2011).
79. Zawahir Z, Dayam R, Deng J, Pereira C, Neamati N. Pharmacophore guided discovery of small-molecule human apurinic/apyrimidinic endonuclease 1 inhibitors. J. Med. Chem. 52, 20-32 (2009).
80. Bapat A, Glass LS, Luo M et al. Novel small-molecule inhibitor of apurinic/apyrimidinic endonuclease 1 blocks proliferation and reduces viability of glioblastoma cells. J. Pharmacol. Exp. Ther. 334, 988-998 (2010).
81. Seiple LA, Cardellina JH II, Akee R, Stivers JT. Potent inhibition of human apurinic/apyrimidinic endonuclease 1 by arylstibonic acids. Mol. Pharmacol. 73, 669-677 (2008). (Pubitemid 351397872)
82. Luo M, Kelley MR. Inhibition of the human apurinic/apyrimidinic endonuclease (APE1) repair activity and sensitization of breast cancer cells to DNA alkylating agents with lucanthone. Anticancer Res. 24, 2127-2134 (2004). (Pubitemid 39166286)
83. Bailly C, Waring MJ. Preferential intercalation at AT sequences in DNA by lucanthone, hycanthone, and indazole analogs. A footprinting study. Biochemistry 32, 5985-5993 (1993). (Pubitemid 23198758)
84. Nyland RL, Luo M, Kelley MR, Borch RF. Design and synthesis of novel quinine inhibitors targeted to the redox function of apurinic/apyrimidinic endonuclease 1/redox enhancing factor-1 (Ape1/Ref-1). J. Med. Chem. 53, 1200-1210 (2010).
85. Manvilla BA, Wauchope O, Seley-Radtke KL, Drohat AC. NMR studies reveal an unexpected binding site for a redox inhibitor of AP endonuclease 1. Biochemistry 50, 10540-10549 (2011).
86. Liu L, Gerson SL. Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr. Opin. Investig. Drugs 5, 623-627 (2004).
87. Baldwin MR, O'Brien PJ. Human AP endonuclease 1 stimulates multiple-turnover base excision by alkyladenine DNA glycosylase. Biochemistry 48, 6022-6033 (2009).
88. Fitzgerald ME, Drohat AC. Coordinating the initial steps of base excision repair. Apurinic/apyrimidinic endonuclease 1 actively stimulates thymine DNA glycosylase by disrupting the product complex. J. Biol. Chem. 283, 32680-32690 (2008).
89. Abyzov A, Uzun A, Strauss PR, Ilyin VA. An AP endonuclease 1-DNA polymerase beta complex: theoretical prediction of interacting surfaces. PLoS Comput. Biol. 4, (2008).
90. Cistulli C, Lavrik OI, Prasad R, Hou E, Wilson SH. AP endonuclease and poly(ADP-ribose) polymerase-1 interact with the same base excision repair intermediate. DNA Repair 3, 581-591 (2004). (Pubitemid 38609048)
91. Ranalli TA, Tom S, Bambara RA. AP endonuclease 1 coordinates flap endonuclease 1 and DNA ligase I activity in long patch base excision repair. J. Biol. Chem. 277, 41715-41724 (2002). (Pubitemid 35257479)
92. Prasad R, Beard WA, Batra VK, Liu Y, Shock DD, Wilson SH. A review of recent experiments on step-to-step 'hand-off' of the DNA intermediates in mammalian base excision repair pathways. Mol. Biol. (Mosk.) 45, 586-600 (2011).
93. Sugo N, Aratani Y, Nagashima Y, Kubota Y, Koyama H. Neonatal lethality with abnormal neurogenesis in mice deficient in DNA polymerase beta. EMBO J. 19, 1397-1404 (2000). (Pubitemid 30151035)
94. Sobol RW, Horton JK, Kühn R et al. Requirement of mammalian DNA polymerase-beta in base-excision repair. Nature 379, 183-186 (1996). (Pubitemid 26020204)
95. Canitrot Y, Cazaux C, Fréchet M et al. Overexpression of DNA polymerase beta in cell results in a mutator phenotype and a decreased sensitivity to anticancer drugs. Proc. Natl Acad. Sci. USA 95, 12586-12590 (1996). (Pubitemid 28483808)
96. Starcevic D, Dalal S, Sweasy JB. Is there a link between DNA polymerase beta and cancer? Cell Cycle 3, 998-1001 (2004). (Pubitemid 40268650)
97. Bhattacharyya N, Banerjee S. A variant of DNA polymerase beta acts as a dominant negative mutant. Proc. Natl Acad. Sci. USA. 94, 10324-10329 (1997). (Pubitemid 27407040)
98. Sawaya MR, Prasad R, Wilson SH, Kraut J, Pelletier H. Crystal structures of human DNA polymerase beta complexed with gapped and nicked DNA: evidence for an induced fit mechanism. Biochemistry 36, 11205-11215 (1997). (Pubitemid 27398440)
99. Deng JZ, Starck SR, Hecht SM, Ijames CF, Hemling ME. Harbinatic acid, a novel and potent DNA polymerase beta inhibitor from Hardwickia binata. J. Nat. Prod. 62, 1000-1002 (1999). (Pubitemid 29357449)
100. Gao Z, Maloney DJ, Dedkova LM, Hecht SM. Inhibitors of DNA polymerase beta: activity and mechanism. Bioorg. Med. Chem. 16, 4331-4340 (2008). (Pubitemid 351539042)
101. Maloney DJ, Deng JZ, Starck SR, Gao Z, Hecht SM. (+)-myristinin A, a naturally occurring DNA polymerase beta inhibitor and potent DNA-damaging agent. J. Am. Chem. Soc. 127, 4140-4141 (2005). (Pubitemid 40463017)
102. Jaiswal AS, Banerjee S, Panda HA et al. A novel inhibitor of DNA polymerase b enhances the ability of temozolomide to impair the growth of colon cancer cells. Mol. Cancer Res. 7, 1973-1983 (2009).
103. Jaiswal AS, Banerjee S, Aneja R, Sarkar FH, Ostrov DA, Narayan S. DNA polymerase b as a novel target for chemotherapeutic intervention of colorectal cancer. PLoS ONE 6, e16691 (2011).
104. Balusu R, Jaiswal AS, Armas ML, Kundu CN, Bloom LB, Narayan S. Structure/function analysis of the interaction of adenomatous polyposis coli with DNA polymerase beta and its implications for base excision repair. Biochemistry 46, 13961-13974 (2007). (Pubitemid 350253072)
105. Narayan S, Jaiswal AS. Activation of adenomatous polyposis coli (APC) gene expression by the DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine requires p53. J. Biol. Chem. 272, 30619-30622 (1997). (Pubitemid 27527492)
106. Markowitz SD, Bertagnolli MM. Molecular basis of colorectal cancer. N. Engl. J. Med. 361, 2449-2460 (2009).
107. Jaiswal AS, Narayan S. A novel function of adenomatous polyposis coli (APC) in regulating DNA repair. Cancer Lett. 271, 272-280 (2008).
108. Kundu CN, Balusu R, Jaiswal AS, Narayan S. Adenomatous polyposis coli-mediated hypersensitivity of mouse embryonic fibroblast cell lines to methylmethane sulfonate treatment: implication of base excision repair pathways. Carcinogenesis 28, 2089-2095 (2007). (Pubitemid 47543367)
109. Kucherlapati M, Yang K, Kuraguchi M et al. Haploinsufficiency of Flap endonuclease (Fen1) leads to rapid tumor progression. Proc. Natl Acad. Sci. USA 99, 9924-9929 (2002). (Pubitemid 34831149)
110. Larsen E, Gran C, Saether BE, Seeberg E, Klungland A. Proliferation failure and gamma radiation sensitivity of Fen1 null mutant mice at the blastocyst stage. Mol. Cell. Biol. 23, 5346-5353 (2003). (Pubitemid 36950889)
111. Tumey LN, Bom D, Huck B et al. The identification and optimization of a N-hydroxy urea series of flap endonuclease 1 inhibitors. Bioorg. Med. Chem. Lett. 15, 277-281 (2005). (Pubitemid 39647135)
112. Pascal JM, O'Brien PJ, Tomkinson AE, Ellenberger T. Human DNA ligase I completely encircles and partially unwinds nicked DNA. Nature 432, 473-478 (2004). (Pubitemid 39576523)
113. Zhong S, Chen X, Zhu X et al. Identification and validation of human DNA ligase inhibitors using computer-aided drug design. J. Med. Chem. 51, 4553-4562 (2008).
114. Chen X, Zhong S, Zhu X et al. Rational design of human DNA ligase inhibitors that target cellular DNA replication and repair. Cancer Res. 68, 3169-3177 (2008).
115. Sun D, Urrabaz R, Nguyen M et al. Elevated expression of DNA ligase I in human cancers. Clin. Cancer Res. 7, 4143-4148 (2001). (Pubitemid 34044639)
116. Khodyreva SN, Prasad R, Ilina ES et al. Apurinic/apyrimidinic (AP) site recognition by the 5'-dRP/AP lyase in poly(ADP-ribose) polymerase-1 (PARP-1). Proc. Natl Acad. Sci. USA 107, 22090-22095 (2010).
117. Eustermann S, Videler H, Yang JC et al. The DNA-binding domain of human PARP-1 interacts with DNA single-strand breaks as a monomer through its second zinc finger. J. Mol. Biol. 407, 149-170 (2011).
118. Zhu G, Chang P, Lippard SJ. Recognition of platinum-DNA damage by poly(ADP-ribose) polymerase-1. Biochemistry. 49, 6177-6183 (2010).
119. Huambachano O, Herrera F, Rancourt A, Satoh MS. Double-stranded DNA binding domain of poly(ADP-ribose) polymerase-1 and molecular insight into the regulation of its activity. J. Biol. Chem. 286, 7149-7160 (2011).
120. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem. J. 342, 249-268 (1999). (Pubitemid 29425344)
121. Herceg Z, Wang Z-Q. Failure of poly(ADP-ribose) polymerase cleavage by caspases leads to induction of necrosis and enhanced apoptosis. Mol. Cell. Biol. 19, 5124-5133 (1999). (Pubitemid 29289550)
122. Masutani M, Suzuki H, Kamada N et al. Poly(ADP-ribose) polymerase gene disruption conferred mice resistant to streptozotocin-induced diabetes. Proc. Natl Acad. Sci. USA 96, 2301-2304 (1999). (Pubitemid 29117909)
123. Pieper AA, Brat DJ, Krug DK et al. Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc. Natl Acad. Sci. USA 96, 3059-3064 (1999). (Pubitemid 29148843)
124. Tentori L, Balduzzi A, Portarena I et al. Poly (ADP-ribose) polymerase inhibitor increases apoptosis and reduces necrosis induced by a DNA minor groove binding methyl sulfonate ester. Cell Death Differ. 8, 817-828 (2001). (Pubitemid 32725533)
125. Ström CE, Johansson F, Uhlén M, Szigyarto CA, Erixon K, Helleday T. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res. 39, 3166-3175 (2011).
126. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921 (2005). (Pubitemid 40559006)
127. Lord CJ, Ashworth A. Targeted therapy for cancer using PARP inhibitors. Curr. Opin. Pharmacol. 8, 363-369 (2008).
128. Lee H, Trainer AH, Friedman LS et al. Involvement of BRCA2 in DNA repair. Mol. Cell 347-357 (1998) (1998). (Pubitemid 128378883)
129. Zhang J, Powell SN. The role of the BRCA1 tumor suppressor in DNA double-strand break repair. Mol. Cancer Res. 3, 531-539 (2005). (Pubitemid 41567272)
130. Karran P. A double strand break repair in mammalian cells. Curr. Opin. Genet. Dev. 10, 144-150 (2000). (Pubitemid 30182246)
131. Graziania G, Szabób C. Clinical perspectives of PARP inhibitors. Pharmacol. Res. 52, 109-118 (2005).
132. Telli ML, Ford JM. PARP inhibitors in breast cancer. Clin. Adv. Hematol. Oncol. 8, 629-635 (2010).
133. Yap TA, Sandhu SK, Carden CP, de Bono JS. Poly(ADP-ribose) polymerase (PARP) inhibitors: Exploiting a synthetic lethal strategy in the clinic. CA Cancer J. Clin. 61, 31-49 (2011).
134. Plummer R, Jones C, Middleton M et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 14, 7917-7923 (2008).
135. Jamieson ER, Lippard SJ. Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99, 2467-2498 (1999).
136. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ercc1-xpf. Biochem. Pharmacol. 60, 1305-1313 (2000).
137. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res. 63, 1311-1131 (2003).
138. Barret J-M, Cadou M, Hill BT. Inhibition of nucleotide excision repair and sensitisation of cells to DNA cross-linking anticancer drugs by F 11782, a novel fluorinated epipodophylloid. Biochem. Pharmacol. 63, 251-258 (2002). (Pubitemid 34158826)
139. Neher TM, Shuck SC, Liu J, Zhang J-T, Turchi JJ. Identification of novel small molecule inhibitors of the XPA protein using in silico based screening ACS Chem. Biol. 5, 953-965 (2010).
140. Neher TM, Bodenmiller D, Fitch RW, Jalal SI and Turchi JJ. Novel irreversible small molecule inhibitors of replication protein a display single-agent activity and synergize with cisplatin. Mol. Cancer Ther. 10, 1796-1806 (2011).
141. Ledermann JA, Gabra H, Jayson GC et al. Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer. Clin. Cancer Res. 16, 4899-4905 (2010).
142. Deans AJ, West SC. DNA interstrand crosslink repair and cancer. Nat. Rev. Cancer 11, 467-480 (2011).
143. Nojima K, Hochegger H, Saberi A et al. Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells. Cancer Res. 65, 11704-11711 (2005). (Pubitemid 41821731)
144. Dronkert ML, Kanaar R. Repair of DNA interstrand cross-links. Mutat Res. 486, 217-247 (2001). (Pubitemid 32763210)
145. Spanswick VJ, Craddock C, Sekhar M et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. Blood 100, 224-229 (2002). (Pubitemid 35177451)
146. Bignami M, O'Driscoll M, Aquilina G, Karran P. Unmasking a killer: DNA O(6)-methylguanine and the cytotoxicity of methylating agents. Mutat. Res. 462, 71-82 (2000). (Pubitemid 30190215)
147. Kohn KW. Interstrand crosslinking of DNA by 1,3-bis(2-chloroethyl)-1- nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas. Cancer Res. 37, 1450-1454 (1977). (Pubitemid 8104887)
148. Baer JC, Freeman AA, Newlands ES, Watson AJ, Rafferty JA, Margison GP. Depletion of O6-alkylguanine-DNA alkyltransferase correlates with potentiation of temozolomide and CCNU toxicity in human tumour cells. Br. J. Cancer 67, 1299-1302 (1993). (Pubitemid 23172868)
149. Ranson M, Middleton MR, Bridgewater J et al. Lomeguatrib, a potent inhibitor of O6-alkylguanine-DNA-alkyltransferase: Phase I safety, pharmacodynamic, and pharmacokinetic trial and evaluation in combination with temozolomide in patients with advanced solid tumors. Clin. Cancer Res. 12, 1577-1584 (2006).
150. Khan OA, Ranson M, Michael M et al. A Phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br. J. Cancer 98, 1614-1618 (2008). (Pubitemid 351684692)